10-Q: Processa Pharmaceuticals Reports Second Quarter 2024 Results, Advances Oncology Pipeline

Processa Pharmaceuticals reported a net loss of $3.01 million for the second quarter of 2024, while progressing its oncology drug pipeline, including initiating a Phase 2 trial for NGC-Cap.

Summary

• Processa Pharmaceuticals, a clinical-stage biopharmaceutical company, announced its financial results for the second quarter of 2024, reporting a net loss of $3.01 million, or $1.01 per share.
• The company's operating loss for the quarter was $3.08 million, with research and development expenses totaling $1.73 million and general and administrative expenses at $1.35 million.
• For the six months ended June 30, 2024, the net loss was $5.74 million, or $2.11 per share.
• The company's cash and cash equivalents stood at $5.57 million as of June 30, 2024.
• Processa is focused on developing Next Generation Chemotherapy (NGC) drugs, including NGC-Cap, NGC-Gem, and NGC-Iri, and has initiated a Phase 2 trial for NGC-Cap in breast cancer.
• The company raised $6.3 million in net proceeds from a public offering in January 2024 and has an at-the-market offering program for up to $2.4 million.
• The company believes its current cash will fund operations into late 2024, but will require additional funding to continue operations beyond that point.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as the initiation of a Phase 2 trial and a new CFO, the company's financial losses, limited cash runway, and legal dispute with Elion create significant concerns. The need for additional funding and the going concern warning further dampen the sentiment.

Positives

• The company has initiated a Phase 2 trial for NGC-Cap in breast cancer, a key milestone for its lead drug candidate.
• The company successfully raised $6.3 million in net proceeds through a public offering, strengthening its financial position.
• The company has established an at-the-market offering program for up to $2.4 million, providing additional financial flexibility.
• The company is ahead of schedule on a key milestone for its license agreement with Elion for NGC-Cap.
• The appointment of a new CFO with extensive pharmaceutical industry experience is a positive development for the company's financial management.
• The company has a clear strategic focus on advancing its pipeline of NGC oncology drugs.

Negatives

• The company reported a net loss of $3.01 million for the second quarter of 2024 and $5.74 million for the six months ended June 30, 2024.
• The company's operating expenses continue to exceed its income, resulting in ongoing losses.
• The company's cash and cash equivalents of $5.57 million are projected to only fund operations into late 2024.
• The company is dependent on additional financing to continue operations and advance its drug pipeline.
• There is substantial doubt about the company's ability to continue as a going concern within one year without additional funding.
• The company is involved in a legal dispute with Elion regarding a license agreement.

Risks

• The company has a limited operating history and a history of losses, which raises concerns about its ability to achieve profitability.
• The company's ability to obtain adequate financing to fund its operations is uncertain, and failure to do so could lead to delays or suspension of clinical trials.
• The company's drug candidates are subject to regulatory approval, and there is no guarantee that they will receive FDA or other governmental approvals.
• The company faces competition from other pharmaceutical companies, which could impact its ability to commercialize its products.
• The company's intellectual property rights are subject to challenges, and the company may be exposed to third-party claims.
• The company's licenses are subject to termination by the licensor in certain circumstances, which could prevent the company from marketing some or all of its products.
• The company is currently involved in a legal dispute with Elion, which could have an adverse effect on its business and results of operations.

Future Outlook

The company expects to use net proceeds from the ATM Offering for continued research and development, especially for its oncology products, and for working capital and general corporate purposes. The company believes its current cash will satisfy operating needs into late 2024, including the beginning of its Phase 2 trial of NGC-Cap in breast cancer. The company plans to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements.

Management Comments

• Management believes that its Regulatory Science Approach provides greater efficiencies, a greater possibility of drug approval, and a greater ability to evaluate the benefit-risk of a drug.
• Management believes that its NGC treatments have the potential to extend the survival and/or quality of life for more patients diagnosed with cancer while decreasing the number of patients who are required to dose-adjust or discontinue treatment because of side effects or lack of response.

Industry Context

The company's focus on improving existing chemotherapy drugs aligns with the industry trend of seeking more effective and safer cancer treatments. The company's approach of modifying existing FDA-approved drugs to improve their safety and efficacy profiles is a common strategy in the pharmaceutical industry. The company's emphasis on regulatory science and the FDA's Project Optimus initiative reflects the increasing importance of efficient and science-based drug development.

Comparison to Industry Standards

• Processa's approach of modifying existing chemotherapy drugs is similar to other companies that focus on drug repurposing or reformulations, such as companies working on improved delivery systems or dosage forms of existing drugs.
• The company's focus on regulatory science and the FDA's Project Optimus initiative is a differentiating factor, as many companies may not have the same level of expertise in this area.
• The company's financial results are typical for a clinical-stage biopharmaceutical company, which often incurs significant losses during the development phase.
• The company's cash position is relatively low compared to some of its peers, which may require it to raise additional capital more frequently.
• The company's legal dispute with Elion is a risk factor that is not uncommon in the pharmaceutical industry, where licensing agreements are often complex and subject to disputes.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in a legal dispute with Elion regarding a license agreement, with the company filing a complaint seeking monetary damages, declaratory judgement and injunctive relief.

Related Party Transactions

• CorLyst, LLC reimburses the company for shared costs related to payroll, health insurance, and rent.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and the potential for a decrease in share value due to the company's financial losses and going concern warning.
• Employees may be impacted by the company's financial instability and potential restructuring or layoffs if additional funding is not secured.
• Customers (potential patients) may benefit from the development of new and improved cancer treatments, but the timeline for these treatments is uncertain.
• Suppliers and creditors face the risk of non-payment if the company is unable to secure additional funding and continue operations.

Next Steps

• The company will continue to advance its Phase 2 trial for NGC-Cap in breast cancer.
• The company will meet with the FDA to discuss potential trial designs for NGC-Gem.
• The company will continue to evaluate manufacturing options for PCS11T (NGC-Iri).
• The company will continue to evaluate options to monetize its non-core drug assets, PCS12852 and PCS499.
• The company will seek additional funding through various means.

Key Dates

Keywords

biopharmaceutical, oncology, clinical trials, NGC-Cap, NGC-Gem, NGC-Iri, cancer, drug development, regulatory science, FDA, financing, reverse stock split